Garima Sharma։ GLP-1 Receptor Agonists Across the Reproductive Life Course
Garima Sharma, Director of Preventive Cardiology and Women’s Cardiovascular health at Inova Health System, shared a post on LinkedIn about a recent article by Sarah Dib et al, published in The Lancet Obstetrics, Gynaecology and Women’s Health, adding:
”The first international consensus recommendations The Lancet Group on the use of GLP-1 receptor agonists across the reproductive life course in women with diabetes were developed by integrating a systematic review and meta-analysis of more than 43 000 women exposed to GLP-1 receptor agonists, expert consensus from 42 specialists with international representation, and input from 60 women with lived experience.
Available evidence, predominantly in women with type 2 diabetes, suggests that there is no increase in congenital anomaly risk following first-trimester discontinuation of GLP-1 receptor agonists, compared with no GLP-1 receptor agonist exposure, but important uncertainties remain regarding pregnancy loss, pregnancy exposure beyond the first trimester, and postpartum use.
The consensus panel supported GLP-1 receptor agonist use for preconception metabolic optimisation where needed in women with type 2 diabetes and recognised potential benefits in women with type 1 diabetes and previous gestational diabetes, although direct evidence in these groups is scarce.
The consensus recommendations should be interpreted in the context of little direct evidence and low certainty. Future studies focused on fertility, breastfeeding and lactation impact etc are needed.”
Title: Preconception, pregnancy, and postnatal use of GLP-1 receptor agonist-based therapies in women with type 1, type 2, or gestational diabetes: a systematic review, meta-analysis, and international expert consensus statement
Authors: Sarah Dib, Matthew J Savage, Dawn Adams, Melanie J Davies, Rita Forde, Angela C Flynn, Paul W Franks, Alison Harte, Ritwika Mallik, Susan E Ozanne, Caroline Ovadia, Dimitris Papamargaritis, Rebecca M Reynolds, Naveed Sattar, Sara G I Suliman, Tricia Tan, Jovanna Tsoutsouki, Georgia Weston, Sara L White, Claire L Meek
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC